Posted by Michael Wonder on 28 Apr 2022
FDA grants BTX 1801 new qualified infectious disease product designation status
28 April 2022 - With the recent completion of additional animal studies, the Phase 2 clinical study for BTX 1801 remains on track to initiate in 2Q 2022.
Clinical dermatology company, Botanix Pharmaceuticals is pleased to announce that the U.S. FDA Office of Antimicrobial Products has granted qualified infectious disease product status for the Botanix novel cannabidiol antibacterial product, BTX 1801.
